Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

https://www.thelancet.com/journals/landia/article/PIIS2213-8587(23)00356-X/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz--z-I3zz1R3hmFrAu0-g_Yod0amOJKgDl_YftZ6wedbL9faW1Hwb36aFWtBq58BhVuDF8gMyrW8FLPtWXG03rIJ1U2uLw&_hsmi=296908066&utm_content=296876759&utm_source=hs_email